Heart safety check for new drug in healthy volunteers
NCT ID NCT06411860
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 30 times
Summary
This completed Phase 1 study checked whether olpasiran, an experimental drug, changes heart rhythm in 32 healthy adults aged 18 to 60. Participants received a single dose of olpasiran, a placebo, or a positive control in a crossover design. The main goal was to measure any effects on the heart's electrical activity (QT interval). The study provides safety data for future development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASIC SCIENCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit Limited - Leeds
Leeds, LS11 9EH, United Kingdom
Conditions
Explore the condition pages connected to this study.